In the journal Brain, experts have unveiled the creation of a test capable of identifying a marker of Alzheimer’s disease within blood samples.
Known as brain-derived tau, or BD-tau, it is regarded as a top performer in comparison to current blood diagnostic tests for Alzheimer’s disease.
“Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer’s disease-type neurodegeneration,” according to researchers.
“Thus, brain-derived tau demonstrates potential to complete the AT(N) scheme in blood, and will be useful to evaluate Alzheimer’s disease-dependent neurodegenerative processes for clinical and research purposes.”
The research was released on December 27, 2022.
